Menu Search
Equities

Pure Biologics SA

PQB:FRA

Pure Biologics SA

Actions
  • Price (EUR)4.69
  • Today's Change-0.255 / -5.16%
  • Shares traded--
  • 1 Year change+63.99%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Pure Biologics SA's revenues fell -85.65% from 662.00k to 95.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 25.60m to a larger loss of 35.69m.
Gross margin-2,439.13%
Net profit margin-48,734.78%
Operating margin-43,546.38%
Return on assets-72.94%
Return on equity-250.95%
Return on investment-99.86%
More ▼

Cash flow in PLNView more

In 2023, Pure Biologics SA increased its cash reserves by 59.63%, or 1.35m. Cash Flow from Financing totalled 24.22m or 25,492.63% of revenues. In addition the company used 23.26m for operations while cash from investing totalled 391.00k.
Cash flow per share-8.96
Price/Cash flow per share--
Book value per share-0.9246
Tangible book value per share-0.9913
More ▼

Balance sheet in PLNView more

Pure Biologics SA has a Debt to Total Capital ratio of 130.23%, a higher figure than the previous year's 89.53%.
Current ratio2.07
Quick ratio--
Total debt/total equity--
Total debt/total capital1.30
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.